相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Stem Cell Property Epithelial-to-Mesenchymal Transition is a Core Transcriptional Network for Predicting Cetuximab (Erbitux (TM)) Efficacy in KRAS Wild-Type Tumor Cells
Cristina Oliveras-Ferraros et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
被撤回的出版物: Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors (Retracted article. See vol. 181, 2023)
Floriana Morgillo et al.
LUNG CANCER (2011)
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
Kihyun Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
AACR Centennial Series: The Biology of Cancer Metastasis: Historical Perspective
James E. Talmadge et al.
CANCER RESEARCH (2010)
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells
Erika Martinelli et al.
CLINICAL CANCER RESEARCH (2010)
A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
Joline S. W. Lind et al.
CLINICAL CANCER RESEARCH (2010)
Annual Review of Advances in Lung Cancer Clinical Research A Report for the Year 2009
Thomas E. Stinchcombe et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
VANDETANIB: AN OVERVIEW OF ITS CLINICAL DEVELOPMENT IN NSCLC AND OTHER TUMORS
A. Morabito et al.
DRUGS OF TODAY (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
George N. Naumov et al.
CLINICAL CANCER RESEARCH (2009)
Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Bart Jacobs et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
Jeet Gandhi et al.
PLOS ONE (2009)
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Kornelia Polyak et al.
NATURE REVIEWS CANCER (2009)
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
Sharon Barr et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
Stuart Thomson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
Kimio Yonesaka et al.
CLINICAL CANCER RESEARCH (2008)
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
Roberto Bianco et al.
CLINICAL CANCER RESEARCH (2008)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
Floriana Morgillo et al.
DIFFERENTIATION (2007)
Expression of snail in pancreatic cancer promotes metastasis and chemoresistance
Tao Yin et al.
JOURNAL OF SURGICAL RESEARCH (2007)
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma
Barbara A. Frederick et al.
MOLECULAR CANCER THERAPEUTICS (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Pre-processing Agilent microarray data
Marianna Zahurak et al.
BMC BIOINFORMATICS (2007)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
Marissa Shrader et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy
JR Tonra et al.
CLINICAL CANCER RESEARCH (2006)
Autocrine activation of PDGFRα promotes the progression of ovarian cancer
D Matei et al.
ONCOGENE (2006)
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells
ML Janmaat et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway
Piotr Smolewski
ANTI-CANCER DRUGS (2006)
Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis
HY Lee et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
分享论文
